Clinical significance of urine heparanase in bladder cancer progression

Neoplasia

Volumn 10, Issue 2, 2008, Pages 125-130

  Shafat, Itay ^a   Pode, Dov ^b   Peretz, Tamar ^b   Ilan, Neta ^a   Vlodavsky, Israel ^a   Nisman, Benjamin ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; URINALYSIS;

EID: 39049173121     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07875     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. Parker SL, Tong T, Bolden S, and Wingo PA (1997). Cancer statistics, 1997. CA Cancer J Clin 47, 5-27.
3. Spiess PE and Czerniak B (2006). Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130, 844-852.
4. Sengupta S and Blute ML (2006). The management of superficial transitional cell carcinoma of the bladder. Urology 67, 48-54.
5. Vlodavsky I and Friedmann Y (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108, 341-347.
6. Dempsey LA, Brunn GJ, and Platt JL (2000). Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25, 349-351.
7. Parish CR, Freeman C, and Hulett MD (2001). Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471, M99-M108.
8. Fjeldstad K and Kolset SO (2005). Decreasing the metastatic potential in cancers - targeting the heparan sulfate proteoglycans. Curr Drug Targets 6, 665-682.
9. Edovitsky E, Elkin M, Zcharia E, Peretz T, and Vlodavsky I (2004). Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96, 1219-1230.
10. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, and Elkin M (2006). Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107, 3609-3616.
11. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, and Marchetti D (2005). Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia 7, 253-262.
12. Ilan N, Elkin M, and Vlodavsky I (2006). Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018-2039.
13. Vreys V and David G (2007). Mammalian heparanase: what is the message? J Cell Mol Med 11, 427-452.
14. Ferro V, Hammond E, and Fairweather JK (2004). The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4, 693-702.
15. McKenzie EA (2007). Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 152, 1-14.
16. Miao HQ, Liu H, Navarro E, Kussie P, and Zhu Z (2006). Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13, 2101-2111.
17. Sanderson RD, Yang Y, Kelly T, Macleod V, Dai Y, and Theus A (2005). Enzymatic remodeling of heparan sulfate proteoglycans within the tumor micro-environment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 96, 897-905.
18. Vlodavsky I, Ilan N, Naggi A, and Casu B (2007). Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13, 2057-2073.
19. Kjellen L and Lindahl U (1991). Proteoglycans: structures and interactions. Annu Rev Biochem 60, 443-475.
20. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, and Zako M (1999). Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777.
21. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, and Vlodavsky I (1988). A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 130, 393-400.
22. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, and Klagsbrun M (1987). Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84, 2292-2296.
23. Ben-Zaken O, Shafat I, Gingis-Velitski S, Bangio H, Kasuto Kelson I, Alergand T, Amor Y, Ben-Yakar Maya R, Vlodavsky I, and Ilan N (2007). Low and high affinity receptors mediate cellular uptake of heparanase. Int J Biochem Cell Biol Online, Sep. 29, 2007.
24. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I, and Ilan N (2004). Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 279, 44084-44092.
25. Shafat I, Vlodavsky I, and Ilan N (2006). Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 281, 23804-23811.
26. Vreys V, Delande N, Zhang Z, Coomans C, Roebroek A, Durr J, and David G (2005). Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280, 33141-33148.
27. Shafat I, Zcharia Z, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I, and Ilan N (2008). An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341, 958-963.
28. Shafat I, Ben-Barak A, Postovsky S, Elhasid R, Ilan N, Vlodavsky I, and Ben Arush MW (2007). Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 9, 909-916.
29. Sobin LH (1977). Standardization and the histopathology of tumours. Histopathology 1, 87-92.
30. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, and Pode D (2002). Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94, 2914-2922.
31. Hanley JA and McNeil BJ (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36.
32. Ishai-Michaeli R, Eldor A, and Vlodavsky I (1990). Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul 1, 833-842.
33. Lokeshwar VB and Selzer MG (2006). Urinary bladder tumor markers. Urol Oncol 24, 528-537.
34. Gohji K, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, and Nakajima M (2001). Heparanase protein and gene expression in bladder cancer. J Urol 166, 1286-1290.
35. Vlodavsky I, Abboud-Jarrous G, Elkin M, Naggi A, Casu B, Sasisekharan R, and Ilan N (2006). The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 35, 116-127.
36. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, and Nakajima M (2001). Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 95, 295-301.
37. Nielsen ME, Schaeffer EM, Veltri RW, Schoenberg MP, and Getzenberg RH (2006). Urinary markers in the detection of bladder cancer: what's new? Curr Opin Urol 16, 350-355.
38. Konety BR (2006). Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 24, 326-337.
39. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, and Shen Y (2005). Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293, 810-816.
40. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, and Shen Y (2006). Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295, 299-305.